<DOC>
	<DOCNO>NCT02154672</DOCNO>
	<brief_summary>The purpose study determine incidence prostate cancer men BRCa2 gene mutation independent indicator prostate cancer screening .</brief_summary>
	<brief_title>Prostate Cancer Screening Men With Germline BRCA2 Mutations</brief_title>
	<detailed_description>This cohort screen study prospectively identify incidence prostate cancer population BRCA2 carrier . All men identify BRCA2 mutation part Yale Cancer Genetic Counseling Program approach offer participation study via program newsletter , BRCA listserv , Facebook page target mailing . Standard care screen Yale Cancer Center men normal prostate cancer risk consist PSA test prostate physical examination begin age 50 year either abnormal MRI prostate follow Fusion-targeted biopsy prostate perform .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>All men â‰¥30 year age least tenyear life expectancy A know BRCA2 mutation Ability MRI Able give inform consent approach participate study If man receive currently receive treatment prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>